SYN - Synthetic Biologics, Inc.
| Previous Close | 0.4950 |
| Open | 0.5111 |
| Bid | 0.4950 x 2900 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.4915 - 0.5400 |
| 52 Week Range | 0.4900 - 9.1000 |
| Volume | 235,151 |
| Avg. Volume | 181,487 |
| Market Cap | 8.654M |
| Beta (3Y Monthly) | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9140 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.25 |
- Simply Wall St.•19 days ago
Those Who Purchased Synthetic Biologics (NYSEMKT:SYN) Shares Three Years Ago Have A 99% Loss To Show For It
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...
- GlobeNewswire•22 days ago
Sýn hf.: Notification of related party trading
See attachment: Attachment NOMX - Viðskipti fjárhagslega tengds aðila 24 05 2019
- Thomson Reuters StreetEvents•24 days ago
Edited Transcript of SYN earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 Synthetic Biologics Inc Earnings Call
- Associated Press•last month
Synthetic Biologics: 1Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 25 cents. In the final minutes of trading on Wednesday, the company's shares hit 61 cents. A year ago, they were trading ...
- PR Newswire•last month
Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results
-- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 -- -- Conference Call Today, May 8, 2019, ...
- PR Newswire•2 months ago
Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019
-- Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET -- ROCKVILLE, Md. , April 30, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of SYN earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 Synthetic Biologics Inc Earnings Call
- PR Newswire•4 months ago
Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results
-- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 -- -- Conference Call Wednesday, February ...
- GlobeNewswire•4 months ago
Sýn hf. : Q4 Investors presentation
See attached: Investors presentation Q4 This announcement is distributed by West Corporation on behalf of West Corporation clients. The issuer of this announcement warrants that they are solely responsible ...
- GlobeNewswire•4 months ago
Sýn hf. : Changes in management of Sýn hf.
Stefán Sigurðsson, the CEO of Sýn hf., has in accordance with an agreement with the Board of Directors, requested to resign from his post, effective as of June 1st 2019. The Board of Directors has requested the Chairman of the Board to take on an active role as regards the organizational structure of the Company as well as ensuring that the operation of the Company will be in good order until a new CEO has been recruited. This announcement is distributed by West Corporation on behalf of West Corporation clients.
- GlobeNewswire•4 months ago
Sýn hf. : Merged company completes its first full year under challenging market conditions
Sýn`s 2018 annual financial statement was approved by Sýn`s CEO and board of directors at a board meeting 27th of February 2019. In December 2017 the company purchased certain assets and operations of 365 Miðlar hf., and this influences the comparison between periods. Sýn and the Faroese company Tjaldur have agreed on heads of terms in the merger of P/F Hey a subsidiary of Sýn and the Faroese IT company Nema a subsidiary of Tjaldur.
- GlobeNewswire•4 months ago
Sýn hf. : Sýn finalizes the merger of Hey P/F with Nema P/F
Reference is made to Stock Exchange announcement from November 1st 2018, according to which Sýn and the Faroese company Tjaldur had agreed heads of terms in relation to a merger of Hey, a subsidiary of Sýn, and the Faroese IT company Nema, a subsidiary of Tjaldur. This announcement is distributed by West Corporation on behalf of West Corporation clients.
- PR Newswire•4 months ago
Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019
-- Conference Call Scheduled for Wednesday, February 27, 2019 at 4:30 p.m. EST -- ROCKVILLE, Md. , Feb. 19, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
- PR Newswire•5 months ago
Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored
ROCKVILLE, Md., Jan. 3, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that the first two patients have been enrolled in SYN-010's Phase 2b investigator-sponsored clinical study. SYN-010 is a proprietary, modified-release reformulation of lovastatin lactone designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). Cedars-Sinai Medical Center (CSMC) and Synthetic Biologics are co-funding the study, which will further assess the efficacy and safety of SYN-010 in patients diagnosed with IBS-C.
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of SYN earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Synthetic Biologics Inc Earnings Call
- GlobeNewswire•6 months ago
Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief Financial Officer (CFO). Mr. Ballantyne is an experienced financial and strategic leader in the biotech, medical device and information services industries with a proven track record of building and strengthening a company’s financial position during his career of more than 25 years. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, commented, “Over the course of his career, Evan has played key roles in successfully leading companies in the full range of strategic options in financing including private equity and public offerings.
- GlobeNewswire•7 months ago
Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•7 months ago
New Trends in Healthcare Push Stocks Higher: 5 Picks
New healthcare trends backed by split party control of Congress are likely to boost industry stocks.
- ACCESSWIRE•7 months ago
New Healthcare Trends Could Push Sector Stocks Higher
CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare.
- PR Newswire•7 months ago
Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development
ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss development of SYN-004 (ribaxamase) for the prevention of antibiotic-mediated Clostridium difficile infection (CDI). Pursuant to the meeting, the FDA has proposed criteria for Phase 3 clinical efficacy and safety which, if achieved, may support submission for marketing approval of ribaxamase on the basis of a single Phase 3 clinical trial.
- Associated Press•7 months ago
Synthetic Biologics: 3Q Earnings Snapshot
The Rockville, Maryland-based company said it had a loss of 93 cents per share. In the final minutes of trading on Thursday, the company's shares hit 88 cents. A year ago, they were trading at $24.30. ...
- PR Newswire•7 months ago
Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results
-- Announced Agreement with Cedars-Sinai Medical Center to Co-fund a Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Strengthened Balance Sheet in Support of ...
- PR Newswire•7 months ago
Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018
-- Conference Call Scheduled for Thursday, November 8, 2018 at 4:30 p.m. EDT -- ROCKVILLE, Md. , Oct. 30, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
- Simply Wall St.•8 months ago
Does Synthetic Biologics Inc (NYSEMKT:SYN) Have A High Beta?
If you own shares in Synthetic Biologics Inc (NYSEMKT:SYN) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- PR Newswire•8 months ago
Synthetic Biologics Announces Closing of $18,639,000 Public Offering
The securities offered by the Company consist of (i) Class A Units consisting of 2,520,000 shares of Common Stock and Warrants to purchase 2,520,000 shares of Common Stock at a combined price of $1.15 per Class A Unit, and (ii) Class B Units consisting of 15,723 shares of Series B Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into an aggregate of 13,672,173 shares of Common Stock, and Warrants to purchase 13,672,173 shares of Common Stock. The Warrants will have an exercise price of $1.38, will be exercisable upon issuance and will expire five years from the date of issuance.
